SCHEMBL320830

SCHEMBL320830

COc1ccc(Cn2c(Cl)cc(=O)n(Cc3ccccc3)c2=O)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RGS4 P49798 1/20 0.53
RGS8 P57771 1/20 0.53
P2RX4 Q99571 1/20 0.51
SIGMAR1 Q99720 1/20 0.50
ADORA3 P0DMS8 1/20 0.49
HPGD P15428 1/20 0.49
KMT2A Q03164 4/20 0.48
MAPK1 P28482 2/20 0.48
TSHR P16473 1/20 0.48
MAPT P10636 5/20 0.48
MEN1 O00255 3/20 0.48
ALDH1A1 P00352 2/20 0.48
POLB P06746 1/20 0.48
GAA P10253 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
THRB P10828 1/20 0.47
TP53 P04637 2/20 0.47
KDM4E B2RXH2 1/20 0.46
ALOX15 P16050 1/20 0.46
CMA1 P23946 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL325735 0.94 MAPT (0.51) RGS4RGS8P2RX4KMT2AMAPK1
SCHEMBL23679701 0.87 MAPT (0.47) RGS4RGS8P2RX4KMT2AMAPK1
SCHEMBL25827018 0.87 HPGD (0.57) RGS4RGS8P2RX4HPGDKMT2A
SCHEMBL4847620 0.83 ALDH1A1 (0.50) RGS4RGS8P2RX4KMT2AMAPK1
SCHEMBL10561978 0.83 PROKR1 (0.48) RGS4RGS8P2RX4ADORA3KMT2A
SCHEMBL18931672 0.82 RGS4 (0.52) RGS4RGS8P2RX4SIGMAR1ADORA3
SCHEMBL19073410 0.82 MAPT (0.47) RGS4RGS8P2RX4KMT2AMAPK1
SCHEMBL19073042 0.82 P2RX3 (0.47) KMT2AMAPTMEN1ALDH1A1KDM4E
SCHEMBL27174639 0.82 RGS4 (0.49) RGS4RGS8P2RX4SIGMAR1ADORA3
SCHEMBL31213524 0.81 HPGD (0.51) ADORA3HPGDKMT2ATSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2585068-A1 PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN Janssen Pharmaceutica, N.V. (BE) 2013-05-01 EP disclosed
EP-1866290-B1 PROKINETICIN 1 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2013-05-01 EP disclosed
EP-1866290-B1 PROKINETICIN 1 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2013-05-01 EP disclosed
US-8362247-B2 Prokineticin 1 receptor antagonists JANSSEN PHARMACEUTICA N.V. (BE) 2013-01-29 US disclosed
US-8362247-B2 Prokineticin 1 receptor antagonists JANSSEN PHARMACEUTICA N.V. (BE) 2013-01-29 US disclosed
US-8362247-B2 Prokineticin 1 receptor antagonists JANSSEN PHARMACEUTICA N.V. (BE) 2013-01-29 US disclosed
US-20120245077-A1 PROKINETICIN 1 RECEPTOR MABUS JOHN R (US) 2012-09-27 US disclosed
US-20120245077-A1 PROKINETICIN 1 RECEPTOR MABUS JOHN R (US) 2012-09-27 US disclosed
US-20120245077-A1 PROKINETICIN 1 RECEPTOR MABUS JOHN R (US) 2012-09-27 US disclosed
US-8188081-B2 Methods of treating inflammation using prokineticin 1 receptor antagonists JANSSEN PHARMACEUTICA, NV (BE) 2012-05-29 US disclosed
EP-1869006-A1 PYRIMIDINDIONE DERIVATIVES AS PROKINETICIN 2 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-26 EP disclosed
EP-1868609-A2 PROKINETICIN 1 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-26 EP disclosed
EP-1866290-A1 PROKINETICIN 1 RECEPTOR ANTAGONISTS Janssen Pharmaceutica, N.V. (BE) 2007-12-19 EP disclosed
US-20070021422-A1 Prokineticin 1 receptor JANSSEN PHARMACEUTICA NV (BE) 2007-01-25 US disclosed
US-20070021422-A1 Prokineticin 1 receptor JANSSEN PHARMACEUTICA NV (BE) 2007-01-25 US disclosed
US-20070021422-A1 Prokineticin 1 receptor JANSSEN PHARMACEUTICA NV (BE) 2007-01-25 US disclosed
US-20060235018-A1 Prokineticin 1 receptor antagonists JANSSEN PHARMACEUTICA N.V. (BE) 2006-10-19 US disclosed
WO-2006104715-A1 PROKINETICIN 1 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-10-05 WO disclosed
WO-2006104713-A1 PYRIMIDINDIONE DERIVATIVES AS PROKINETICIN 2 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-10-05 WO disclosed
WO-2006102112-A2 PROKINETICIN 1 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060235018-A1 Prokineticin 1 receptor antagonists PROKR1, PROKR2, GIPR RGS4 1192/4885RGS8 547/4885P2RX4 1034/4885
US-20070021422-A1 Prokineticin 1 receptor PROKR1, PROKR2, GIPR RGS4 1336/4885RGS8 551/4885P2RX4 1005/4885
US-20120245077-A1 PROKINETICIN 1 RECEPTOR PROKR1, PROKR2, GIPR RGS4 1336/4885RGS8 551/4885P2RX4 1005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.